Inhibition of polymorphic human carbonyl reductase 1 (CBR1) by the cardioprotectant flavonoid 7-monohydroxyethyl rutoside (monoHER)

Pharmaceutical Research

Volumn 25, Issue 7, 2008, Pages 1730-1734

  Gonzalez Covarrubias, Vanessa ^a   Kalabus, James L ^a   Blanco, Javier G ^a  

^a UNIVERSITY AT BUFFALO   (United States)

Author keywords

Anthracycline related cardiotoxicity; Cardioprotectant; Genotype; Human carbonyl reductase 1 (CBR1); MonoHER

Indexed keywords

7 MONOHYDROXYETHYLRUTOSIDE; 7 TRIHYDROXYETHYLRUTOSIDE; CARBONYL REDUCTASE; CARBONYL REDUCTASE 1; DAUNORUBICIN; DOXORUBICIN; FLAVONOID; MENADIONE; QUERCETIN;

ARTICLE; COMPETITIVE INHIBITION; CONCENTRATION RESPONSE; ENZYME INHIBITION; ENZYME KINETICS; ENZYME POLYMORPHISM; ENZYME SUBSTRATE; GENOTYPE; HEART PROTECTION; IC 50; PRIORITY JOURNAL;

ALCOHOL OXIDOREDUCTASES; ANTIBIOTICS, ANTINEOPLASTIC; CARDIOTONIC AGENTS; DATA INTERPRETATION, STATISTICAL; DAUNORUBICIN; DOXORUBICIN; ENZYME INHIBITORS; GENOTYPE; HUMANS; HYDROXYETHYLRUTOSIDE; KINETICS; RECOMBINANT PROTEINS;

EID: 44749085662     PISSN: 07248741     EISSN: 1573904X     Source Type: Journal    
DOI: 10.1007/s11095-008-9592-5     Document Type: Article

References (19)

1. G. Minotti, S. Recalcati, P. Menna, E. Salvatorelli, G. Corna, and G. Cairo. Doxorubicin cardiotoxicity and the control of iron metabolism: quinone-dependent and independent mechanisms. Methods Enzymol. 378:340-361 (2004).
2. A. Slupe, B. Williams, C. Larson, L. M. Lee, T. Primbs, A. J. Bruesch, C. Bjorklund, J. Peloquin, D. L. Warner, S. E. Shadle, H. A. Gambliel, B. J. Cusack, R. D. Olson, H. A. Charlier, and. Reduction of 13-deoxydoxorubicin and daunorubicinol anthraquinones by human carbonyl reductase. Cardiovasc. Toxicol. 5:365-376 (2005).
3. G. L. Forrest, S. Akman, J. Doroshow, H. Rivera, and W. D. Kaplan. Genomic sequence and expression of a cloned human carbonyl reductase gene with daunorubicin reductase activity. Mol. Pharmacol. 40:502-507 (1991).
4. B. Gonzalez, S. Akman, J. Doroshow, H. Rivera, W. D. Kaplan, and G. L. Forrest. Protection against daunorubicin cytotoxicity by expression of a cloned human carbonyl reductase cDNA in K562 leukemia cells. Cancer Res. 55:4646-4650 (1995).
5. R. D. Olson, P. S. Mushlin, D. E. Brenner, S. Fleischer, B. J. Cusack, B. K. Chang, and R. J. Boucek. Doxorubicin cardiotoxicity may be caused by its metabolite, doxorubicinol. Proc. Natl. Acad. Sci. U. S. A. 85:3585-3589 (1988).
6. B. J. Cusack, P. S. Mushlin, L. D. Voulelis, X. D. Li, R. J. Boucek, and R. D. Olson. Daunorubicin-induced cardiac injury in the rabbit: a role for daunorubicinol? Toxicol. Appl. Pharmacol. 118:177-185 (1993).
7. A. Mordente, E. Meucci, M. Giuseppe Ettore, G. Bruno, and M. Giorgio. Human heart cytosolic reductases and anthracycline cardiotoxicity. IUBMB Life. 52:83-88 (2001).
8. V. Gonzalez-Covarrubias, D. Ghosh, S. S. Lakhman, L. Pendyala, and J. G. Blanco. A functional genetic polymorphism on human carbonyl reductase 1 (CBR1 V88I) impacts on catalytic activity and NADPH binding affinity. Drug Metab. Dispos. 35:973-980 (2007).
9. A. Willems, A. Bruynzeel, M. Kedde, C. Groeningen, A. Bast, and W. Vijgh. A phase I study of monohydroxyethylrutoside in healthy volunteers. Cancer Chemother. Pharmacol. 57:678-684 (2006).
10. M. A. I. Abou El Hassan, M. A. Kedde, U. T. H. Zwiers, A. Bast, and W. J. F. van der Vijgh. The cardioprotector monoHER does not interfere with the pharmacokinetics or the metabolism of the cardiotoxic agent doxorubicin in mice. Cancer Chemother. Pharmacol. 51:306-310 (2003).
11. A. M. E. Bruynzeel, H. W. M. Niessen, J. G. F. Bronzwaer, J. J. M. Van Der Hoeven, J. Berkhof, A. Bast, W. J. F. Van Der Vijgh, and C. J. Van Groeningen. The effect of monohydroxyethylrutoside on doxorubicin-induced cardiotoxicity in patients treated for metastatic cancer in a phase II study. Br. J. Cancer. 97:1084-1089 (2007).
12. K. M. Janisch, G. Williamson, P. Needs, and G. W. Plumb. Properties of quercetin conjugates: modulation of LDL oxidation and binding to human serum albumin. Free Radical Res. 38:877-884 (2004).
13. H. Kaiserova, T. Simunek, W. J. F. van der Vijgh, A. Bast, and E. Kvasnickova. Flavonoids as protectors against doxorubicin cardiotoxicity: role of iron chelation, antioxidant activity and inhibition of carbonyl reductase. Biochim. Biophys. Acta. 1772:1065-1074 (2007).
14. F. A. A. van Acker, E. Boven, K. Kramer, G. R. M. M. Haenen, A. Bast, and W. J. F. van der Vijgh. Frederine, a new and promising protector against doxorubicin-induced cardiotoxicity. Clin. Cancer Res. 7:1378-1384 (2001).
15. A. Bast, G. R. M. M. Haenen, A. M. E. Bruynzeel, and W. J. F. Van Der Vijgh. Protection by flavonoids against anthracycline cardiotoxicity: from chemistry to clinical trials. Cardiovasc. Toxicol. 7:154-159 (2007).
16. B. Wermuth. Purification and properties of an NADPH-dependent carbonyl reductase from human brain. Relationship to prostaglandin 9-ketoreductase and xenobiotic ketone reductase. J. Biol. Chem. 256:1206-1213 (1981).
17. K. M. Bohren, J. P. Von Wartburg, and B. Wermuth. Kinetics of carbonyl reductase from human brain. Biochem. J. 244:165-171 (1987).
18. S. S. Lakhman, D. Ghosh, and J. G. Blanco. Functional significance of a natural allelic variant of Human Carbonyl Reductase 3 (CBR3). Drug. Metab. Dispos. 33:254-257 (2005).
19. I. H. Segel. Enzyme kinetics-behavior and analysis of rapid equilibrium and steady-state enzyme systems. Wiley, New York, 1993.